|
Jul 27
|
Pharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutions
|
|
Jul 24
|
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Jul 23
|
Wall Street Set to Open Higher Wednesday; Dow Rises on Japan Trade Deal
|
|
Jul 23
|
US Stock Futures Edge Higher in Wednesday's Premarket Ahead of Housing, Oil Data
|
|
Jul 23
|
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jul 22
|
Pharvaris Announces Proposed Public Offering of Ordinary Shares
|
|
Jul 10
|
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
|
|
Jun 27
|
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
|
|
Jun 16
|
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
|
|
Oct 16
|
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
|
|
Oct 15
|
Pharvaris to Host Virtual Investor Event on October 23, 2024
|
|
Oct 3
|
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
|
|
May 8
|
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Dec 8
|
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
|
|
Dec 7
|
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
|
|
Dec 7
|
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
|
|
Dec 6
|
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
|
|
Dec 6
|
Pharvaris shares spike as drug appears to prevent symptoms of rare disorder
|
|
Dec 6
|
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
|
|
Nov 30
|
Pharvaris to Present at the GA²LEN UCARE Conference 2023
|